Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 2/20 | 0.43 |
| ▸ | CETP | P11597 | 10/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578818 | 0.83 | CETP (0.44) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL971430 | 0.83 | NOTCH1 (0.41) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL713237 | 0.82 | CETP (0.44) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL711884 | 0.82 | CETP (0.43) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL972797 | 0.82 | NOTCH1 (0.42) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL4579478 | 0.81 | CETP (0.44) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL972055 | 0.76 | GSK3A (0.39) | NOTCH1CETPGSK3AMEN1KMT2A | |
| SCHEMBL6027927 | 0.74 | TSHR (0.50) | GSK3AMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL973087 | 0.73 | NOTCH1 (0.47) | NOTCH1GSK3AMEN1KMT2AALDH1A1 | |
| SCHEMBL14491044 | 0.72 | GSK3A (0.49) | NOTCH1CETPGSK3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703793-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8703793-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8703793-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2268644-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2268644-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009109549-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | COQ8A, TNNT2, TBXA2R | NOTCH1 4727/4885CETP 1170/4885GSK3A 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.